ScienceFDA approves Lilly’s Inluriyo–Verzenio combination for an advanced form of breast cancer
STAT reports that a Phase 3 study showed the combination cut the risk of progression or death by 47% compared with imlunestrant alone.
TLDR
STAT reports that the FDA approved Eli Lilly’s Inluriyo in combination with its cancer drug Verzenio for patients with an advanced form of breast cancer. The outlet says a Phase 3 study showed the combination cut the risk of progression or death by 47% compared with imlunestrant alone.
FDA approves Lilly’s Inluriyo–Verzenio combination for an advanced form of breast cancer
STAT reports that a Phase 3 study showed the combination cut the risk of progression or death by 47% compared with imlunestrant alone.
TLDR
STAT reports that the FDA approved Eli Lilly’s Inluriyo in combination with its cancer drug Verzenio for patients with an advanced form of breast cancer. The outlet says a Phase 3 study showed the combination cut the risk of progression or death by 47% compared with imlunestrant alone.